Athersys to Participate in International Stroke Conference and BioProcess International
31 January 2023 - 3:20AM
Business Wire
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative
medicine company developing MultiStem® (invimestrocel) for critical
care indications, announced today its participation in two upcoming
conferences, the International Stroke Conference 2023 (ISC) from
February 8-10, 2023 in Houston, TX and BioProcess International US
West from February 27-March 2, 2023 in San Diego, CA. Any
registered attendees interested in meeting with Athersys at either
conference can contact Ellen Gurley at ir@athersys.com to set up a
meeting.
Hosted by the American Heart Association, ISC is the world’s
premier meeting for clinicians and scientists dedicated to
advancing research and treatment of cerebrovascular disease and
brain health. Attending the conference provides the opportunity to
collaborate with thousands of colleagues in the stroke field from
around the world. Please visit
https://professional.heart.org/en/meetings/international-stroke-conference
for additional information and registration.
Additionally, Senthil Ranganathan, Vice President of Technical
Operations, will be attending and speaking at the BioProcess
International US West conference in San Diego. On March 1, Senthil
will be giving a talk titled, “The Path to Commercialization of an
Allogeneic Stem Cell Therapy: a MultiStem® Perspective.” Details on
his session are below. Please visit
https://informaconnect.com/bpi-west/ for additional information and
registration.
Event:
The Path to Commercialization of
an Allogeneic Stem Cell Therapy: a MultiStem® Perspective
Date:
Wednesday, March 1, 2023
Time:
11:00 AM Pacific Time
Location:
San Diego Convention Center, 111
W Harbor Dr, San Diego, CA 92101
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, inflammatory and immune, and other
critical care indications and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. Investors and others should note that we may
post information about the Company on our website at
www.athersys.com and/or on our accounts on Twitter, Facebook,
LinkedIn or other social media platforms. It is possible that the
postings could include information deemed to be material
information. Therefore, we encourage investors, the media and
others interested in the Company to review the information we post
on our website at www.athersys.com and on our social media
accounts. Follow Athersys on Twitter at www.twitter.com/athersys.
Information that we may post about the Company on our website
and/or on our accounts on Twitter, Facebook, LinkedIn or other
social media platforms may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties. You should not place
undue reliance on forward-looking statements contained on our
website and/or on our accounts on Twitter, Facebook, LinkedIn or
other social media platforms, and we undertake no obligation to
publicly update forward-looking statements, whether as a result of
new information, future events or otherwise.
About MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented
regenerative medicine product in clinical development that has
shown the ability to promote tissue repair and healing in a variety
of ways, such as through the production of therapeutic factors in
response to signals of inflammation and tissue damage. MultiStem
therapy’s potential for multidimensional therapeutic impact
distinguishes it from traditional biopharmaceutical therapies
focused on a single mechanism of benefit. The therapy represents a
unique "off-the-shelf" stem cell product that can be manufactured
in a scalable manner, may be stored for years in frozen form, and
is administered without tissue matching or the need for immune
suppression. Based upon its efficacy profile, its novel mechanisms
of action, and a favorable and consistent tolerability demonstrated
in clinical studies, we believe that MultiStem therapy could
provide a meaningful benefit to patients, including those suffering
from serious diseases and conditions with unmet medical need.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230130005553/en/
Athersys Ellen Gurley Manager of Corporate Communications
and Investor Relations ir@athersys.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024